Search clinical trials for: ABT-530

Total 8846 results

AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
AbbVie

Terminated

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
US Department of Veterans Affairs

Completed

Behavioral Treatments for Chronic Pain

Intractable Pain

United States
AbbVie

Completed

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

HCV Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
AbbVie

No longer available

Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
M.D. Anderson Cancer Center

Completed

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Hematological Malignancies

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Canada, Singapore, Taiwan
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain

Healthy Volunteers

Canada
Abbott

Completed

A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans

Healthy

United States
Abbott

Completed

A Study of ABT-751 in Patients With Colorectal Cancer

Colorectal Cancer

United States
Abbott

Completed

A Study of ABT-751 in Patients With Renal Cell Cancer

Renal Cell Cancer

Canada, United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

Asthma

United Kingdom
AbbVie

Active, not recruiting

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Acute Ischemic Stroke

United States, Australia, Canada, Japan, Korea, Republic of, Spain
Clinic for Cardiovascular Diseases Magdalena

Completed

Allogenic Blood Transfusion During Elective Open Abdominal Aortic Surgery

Blood Transfusion
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States, Russian Federation, United Kingdom
AbbVie

Terminated

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Mild Cognitive Impairment | Alzheimer's Disease

United States
AbbVie

Completed

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

Schizophrenia
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

Diabetic Neuropathic Pain

United States, Czech Republic, France, Germany, Italy, Spain, United Kingdom
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Healthy Volunteers

Healthy Volunteers

United States
Abbott

Completed

A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

Healthy Volunteers

United States
Abbott

Completed

Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers

Healthy

United States
Abbott

Completed

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

Hepatitis C

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
VA Office of Research and Development

Recruiting

Treatments for Insomnia in Veterans With PTSD

PTSD | Insomnia

United States
Abbott

Completed

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

HCV Infection

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
AbbVie

Completed

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Absolute Bioavailability

United Kingdom
Kathleen Ludwig

Available

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Relapsed Childhood ALL | Relapsed Childhood Lymphoblastic Lymphoma

United States
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
AbbVie (prior sponsor, Abbott)

Completed

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States
AbbVie

Completed

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Acute Kidney Injury

United States, Denmark
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie

Completed

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

3

Subscribe